Clorox (NYSE:CLX – Get Rating) updated its FY22 earnings guidance on Monday. The company provided earnings per share guidance of $4.05-4.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.18. The company issued revenue guidance of $7.05-7.27 billion, compared to the consensus revenue estimate of $7.16 billion.
A number of research firms have recently weighed in on CLX. UBS Group dropped their price target on shares of Clorox from $163.00 to $148.00 and set a sell rating for the company in a research report on Friday, February 4th. Atlantic Securities cut shares of Clorox from a neutral rating to an underweight rating and set a $118.00 price objective on the stock. in a research note on Friday, February 4th. Credit Suisse Group decreased their price objective on shares of Clorox from $160.00 to $155.00 and set an underperform rating on the stock in a research note on Friday, February 4th. Wells Fargo & Company lifted their price objective on shares of Clorox from $120.00 to $130.00 in a research note on Tuesday. Finally, Barclays decreased their price objective on shares of Clorox from $132.00 to $117.00 and set an underweight rating on the stock in a research note on Friday, April 1st. Ten equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Sell and a consensus price target of $149.00.
NYSE CLX opened at $143.28 on Tuesday. The firm’s fifty day moving average price is $141.74 and its two-hundred day moving average price is $157.68. The stock has a market cap of $17.60 billion, a PE ratio of 72.00, a PEG ratio of 4.85 and a beta of 0.18. Clorox has a fifty-two week low of $127.02 and a fifty-two week high of $191.75. The company has a debt-to-equity ratio of 3.84, a quick ratio of 0.36 and a current ratio of 0.67.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 13th. Stockholders of record on Wednesday, April 27th will be issued a dividend of $1.16 per share. The ex-dividend date is Tuesday, April 26th. This represents a $4.64 dividend on an annualized basis and a dividend yield of 3.24%. Clorox’s dividend payout ratio (DPR) is presently 233.17%.
Large investors have recently modified their holdings of the company. Neo Ivy Capital Management acquired a new position in shares of Clorox during the fourth quarter worth $97,000. HB Wealth Management LLC acquired a new position in shares of Clorox during the fourth quarter worth $206,000. Paradigm Financial Partners LLC acquired a new position in shares of Clorox during the fourth quarter worth $253,000. Zullo Investment Group Inc. acquired a new position in shares of Clorox during the fourth quarter worth $403,000. Finally, Integrated Wealth Concepts LLC lifted its holdings in Clorox by 30.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 4,297 shares of the company’s stock valued at $749,000 after buying an additional 995 shares during the period. Institutional investors own 77.28% of the company’s stock.
About Clorox (Get Rating)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.
Further Reading
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- It’s Time to Book an Appointment for Teladoc Stock
- Saia Growth Accelerates But It May Not MatterĀ
- GitLab Stock is Trying to Put in a Bottom Here
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.